Related by context. All words. (Click for frequent words.) 79 Granted Orphan Drug 78 Receives Fast Track 76 Fast Track Status 74 Orphan Status 74 Receives Orphan Drug 72 orphan medicinal product 72 Orphan Drug designation 72 Orphan Drug status 72 Orphan Medicinal Product 72 Accelerated Approval 71 Orphan Designation 71 Grants Orphan Drug 71 Orphan Drug designations 71 Orphan Drug Designation 70 orphan designation 70 Orphan Drug 69 Fast Track designations 69 Orphan Drug Status 69 Patent Covering 69 Meets Primary Endpoint 68 Patient Enrollment 68 Personalized Immunotherapy 68 FDA Accepts 68 Expanded Indication 68 NDA Submission 68 Receives Orphan Drug Designation 68 Phase III Clinical Trial 68 Orphan designation 68 Submits NDA 68 Files IND 68 Phase 2b Clinical Trial 68 Orphan Drugs 68 Fast Track Designation 68 Psoriasis Drug 67 Civacir 67 Positive Opinion 67 OMP designation 67 FOLOTYN ® 67 Priority Review 67 MAGE A3 ASCI 67 Bafetinib 67 Archexin 67 Pafuramidine 67 GATTEX TM 67 Completes Patient Enrollment 66 Pivotal Phase III 66 Liprotamase 66 Initiates Clinical Trial 66 Investigational Compound 66 orphan drug 66 Mylan Receives Approval 66 Kepivance 66 Iluvien ® 66 Maribavir 66 Aviptadil 66 Investigational Treatment 66 Milestone Payments 65 Crofelemer budesonide foam 65 PDUFA Date 65 rilonacept 65 Cellegesic 65 Pivotal Trial 65 Initiates Enrollment 65 Initiates Clinical 65 Bazedoxifene 65 small molecule Hedgehog 65 Panzem R 65 First Patient Enrolled 65 Phase IIb Trial 65 Milestone Payment 65 Generic Version Of 65 Argatroban 65 Submits Biologics License Application 65 BiovaxID TM 65 refractory chronic lymphocytic 65 Initiate Clinical Trial 65 vapreotide acetate 65 Valortim TM 65 Anti Tumor 65 Adjuvant Treatment 65 severe gastroparesis 65 Romiplostim 65 Initiates Phase II 65 Marketing Authorisation 64 Belimumab 64 GRAS Status 64 SABER ™ 64 granted Orphan Drug 64 UPLYSO 64 Somatuline Depot 64 Vandetanib 64 Initiates Phase III 64 Single Dose 64 HCV Protease Inhibitor 64 Drug Candidate 64 Advanced Melanoma 64 mertansine 64 MEK Inhibitor 64 R lenalidomide 64 HQK 64 Pralatrexate 64 Pegloticase 64 Receives Milestone Payment 64 FDA Clearance 64 Expedited Review 64 Peginterferon alfa 2b 64 Epratuzumab 64 Aryplase 64 Elagolix 64 Sapacitabine 64 Pivotal Phase 64 VIVITROL ® 64 targeted radiotherapeutic 64 Orphan medicinal 64 Xcytrin R 64 BYETTA ® 64 Cutaneous T 64 Novel Antibiotic 64 ELADUR ™ 64 pralatrexate injection folate analogue 64 Patient Enrolment 64 Advanced Renal Cell 64 Etanercept 64 Kuvan R 64 COLAZAL R 64 C1 Inhibitor 64 granted orphan medicinal 64 highly purified pasteurized 64 proteasome inhibitor 64 Phase 1b Clinical Trial 64 Glatiramer Acetate 64 Dapagliflozin 64 IL# PE#QQR 64 Tezampanel 64 Milestone Payment From 64 JAK2 Inhibitor 64 Cetrorelix 64 RNAi Therapeutic 64 DOR BioPharma Announces 64 Receives Approvable Letter 64 Phase 2a Trial 63 Metastatic Melanoma 63 Amrubicin 63 Phase III Trials 63 Clinical Trial Results 63 Initiate Phase III 63 TRANSDUR ® 63 Ridaforolimus 63 Hsp# Inhibitor 63 Elesclomol 63 R bendamustine hydrochloride 63 Pivotal Study 63 Bayer Onyx 63 Patients Treated With 63 Supplemental Biologics License Application 63 Systemic Delivery 63 dasatinib Sprycel ® 63 Investigational Agent 63 Rheumatoid Arthritis Drug 63 Announces Tentative Approval 63 Survival Benefit 63 Icatibant 63 Exclusive License 63 Aflibercept 63 Traficet EN 63 BRILINTA 63 Lambert Eaton Myasthenic 63 GVAX cancer 63 Evoltra ® 63 Submits Supplemental 63 Arimoclomol 63 delivers fluocinolone acetonide FA 63 Orapred ODT 63 investigational pharmacologically unique 63 Testosterone Gel 63 Combination REOLYSIN R 63 Drug Eluting Stent System 63 Trobalt 63 VISICOL R 63 JAK Inhibitor 63 Prolongs Survival 63 Lupus Drug 63 sorafenib tablets 63 TRANSDUR ™ 63 TYZEKA 63 Completes Enrollment 63 Hycamtin 63 Initiate Phase 63 Receives Marketing Authorization 63 Febuxostat 63 Marketing Authorization 63 Campath ® 63 investigational humanized monoclonal antibody 63 Investigational Drug 63 XIAFLEX ™ 63 Presents Preclinical Data 63 Zenpep 63 First Patient Treated 63 Ostarine ™ 63 Bezielle 63 oral prodrug 63 Friedreich Ataxia FRDA 63 Fibrillex TM 63 Oracea TM 63 Ozarelix 63 BENLYSTA ® 63 Patent Broadly Covering 63 Generic Version 63 ANDA Filing 63 Synerx Pharma 63 BAL# [002] 63 RAPTIVA 63 vitreoretinal disorders 63 Methylnaltrexone 63 Vaccine Adjuvant 63 ZALBIN 63 Resubmission 63 Receive Milestone Payment 63 Epidermal Growth Factor Receptor 63 Completes Patient Enrolment 62 OMNARIS HFA 62 Schizophrenia Drug 62 Phase III Trial 62 First Patient Dosed 62 Therapeutic Discovery Project 62 Million Milestone Payment 62 Cethrin 62 Oral Cladribine 62 Ranolazine 62 LibiGel ® 62 Syndrome LEMS 62 investigational monoclonal antibody 62 Lung Cancer Drug 62 Epilepsy Drug 62 FDA Approvals 62 Phase IIb Clinical Trial 62 Taro Receives 62 lucinactant 62 Dose Escalation 62 RNAi Therapeutics 62 Tarceva TM 62 Ceflatonin ® 62 Silodosin 62 FDA Approvable Letter 62 nasal calcitonin product 62 Phase 2b Trial 62 Phenoptin 62 IMiDs 62 LHRH antagonist 62 Sagent Pharmaceuticals Announces 62 HDAC Inhibitor 62 Gamunex C 62 Antibody Drug Conjugate 62 Albugon 62 Oral Calcitonin 62 histone deacetylase HDAC inhibitor 62 LUCASSIN 62 Phase 2a Clinical Trial 62 Increlex R 62 Teva Provides Update 62 liver resection surgeries 62 methylnaltrexone bromide 62 Golimumab 62 Pirfenidone 62 OMAPRO ™ 62 EVIZON TM 62 MyVax R 62 Product Designation 62 Prospective Randomized 62 Cardium Therapeutics TM 62 Preclinical Data 62 CysDisplay R 62 Gout Drug 62 Firazyr 62 Alemtuzumab 62 ThermoDox R 62 RANK Ligand inhibitor 62 Achieves Primary Endpoint 62 IND Application 62 novel histone deacetylase 62 vemurafenib 62 Noxafil 62 Marketing Authorisation Application 62 MOVIPREP R 62 Actemra tocilizumab 62 rasagiline tablets 62 Zenvia ™ 62 JOULFERON 62 Hepatocellular Carcinoma 62 XIAFLEX ® 62 DORIBAX 62 experimental immunotherapeutics antivirals AmpligeGI mucosa resulting 62 Glufosfamide 62 successfully commercialize Iluvien 62 Files Investigational 62 Successfully Completes Phase 62 Ganite ® 62 Trial Evaluating 62 Clolar ® 62 Aurexis 62 Fabry Disease 62 Muraglitazar 62 R sorafenib tablets 62 Octreolin 62 Zorbtive TM 62 Ixempra 62 Reports Preclinical Data 62 SBIR Grant 62 Ofatumumab 62 AVASTIN 62 Receives Tentative FDA 62 Antitumor Activity 62 MAb therapy 62 Clofarabine 61 novel oral anticoagulant 61 dextromethorphan quinidine 61 drug ISA# 61 Indaflex TM 61 IND Filing 61 Bevacizumab 61 Prostate Cancer Vaccine 61 STELARA TM 61 ZEVALIN ® 61 RELISTOR ® 61 Gaucher Disease 61 diarrhea predominant irritable 61 HuMax CD4 61 Application BLA 61 Metformin HCl 61 SNT MC# 61 treat chronic sinusitis 61 PrevOnco 61 targeting CD# 61 Development OOPD 61 Therapeutic Competitors Companies 61 Factor VIIa 61 CEQ# 61 Daclizumab 61 Romidepsin 61 Yondelis ® 61 SYCREST 61 Completes Dosing 61 GTC recombinant human 61 PNP inhibitor 61 Toremifene 61 Recombinant Human 61 Aztreonam Lysine 61 CYT# potent vascular disrupting 61 Vitrasert R 61 SinuNase TM 61 YONDELIS 61 candidate TNFerade biologic 61 Migraine Drug 61 Somatuline R Autogel R 61 Mipomersen 61 Improved Survival 61 Panzem R NCD 61 ASP# 61 Monoclonal Antibody 61 Ciclesonide 61 Ustekinumab 61 IgG1 monoclonal antibody 61 Metabolic Disorder 61 Fortical R 61 ARRY # 61 Efficacy Trial 61 Anidulafungin 61 receptor tyrosine kinase inhibitor 61 Torisel 61 Presents Positive 61 Study Evaluating 61 Receives Positive Opinion 61 CIP TRAMADOL ER 61 TNF Tumor Necrosis Factor 61 Pathway Inhibitor 61 Protease Inhibitor 61 Shows Efficacy 61 Granulocyte Colony Stimulating Factor 61 Metastatic Colorectal Cancer 61 Behcet uveitis 61 orally administered inhibitor 61 formerly LymphoStat B 61 Loramyc R 61 Initiates Dosing 61 Generic Versions 61 Rotavirus Vaccine 61 Onconase 61 Cholesterol Lowering Drug 61 reslizumab 61 pediatric Crohn disease 61 Inhaled Insulin 61 Cethromycin 61 Cloretazine 61 PRN FDA Approves 61 ALN TTR 61 ADP receptor antagonist 61 IMiDs R 61 Demonstrates Efficacy 61 Eligard R 61 Protexia R 61 systemic immunosuppressive drugs 61 REVLIMID R 61 Raptiva R 61 Topline Results 61 5 lipoxygenase inhibitor 61 Eculizumab 61 Complete Response 61 Sanvar R 61 COLAZAL ® 61 Receives Complete Response 61 Begin Clinical Trials 61 Complicated Skin 61 Ceflatonin 61 Acute Attacks 61 briakinumab 61 Loxapine 61 Loramyc ™ 61 AAG geldanamycin analog 61 Isavuconazole 61 ABILIFY ® 61 alefacept 61 Therapy Evaluation 61 Long Term Efficacy 61 Well Tolerated 61 Tyrosine Kinase Inhibitor 61 Aeolus Pharmaceuticals Announces 61 label Lipofen R 61 ketolide antibiotic 61 Submits Response 61 REBETOL combination therapy 61 Aliskiren 61 ALN PCS 61 Anticancer Agent 61 motexafin gadolinium Injection 61 investigational oral inhibitor 61 ARIXTRA R 61 Acute Heart Failure 61 torezolid phosphate 61 Present Preclinical Data 61 Desvenlafaxine 61 Intravenous Formulation 61 Preotact R 61 autologous cellular immunotherapy 61 acetonide FA 61 Horizant ™ 61 Carfilzomib 61 Simulect 61 Subpart E 61 NEUMUNE 61 cinacalcet HCl 61 Blood Pressure Drug 61 Tanespimycin 60 Launches Generic Version 60 Trastuzumab DM1 60 thalidomide Thalomid 60 HuMax TAC 60 TRISENOX ® 60 L BLP# 60 non nucleoside inhibitor 60 topically applied SEPA 60 ONGLYZA ™ 60 Confirmatory Phase 60 Immunotherapeutic 60 Gleevec imatinib mesylate 60 Campto 60 TEMODAL 60 Soliris eculizumab 60 GTC recombinant form 60 Velaglucerase Alfa 60 Dupuytren Contracture 60 novel emulsion formulation 60 Generx TM 60 Fungal Infections 60 Etravirine 60 mild vasodilator 60 Efficacy Results 60 VitiGam TM 60 Qualified Therapeutic Discovery 60 virus HCV protease inhibitor 60 Annamycin 60 albinterferon alfa 2b 60 Nabi HB Intravenous 60 NUEDEXTA ™ 60 gabapentin enacarbil 60 IMiDs ® compound 60 Benazepril 60 Fast Track designation 60 Teflaro 60 Perifosine 60 k Clearance 60 PEGylated Fab fragment 60 Eszopiclone 60 Enzyme Replacement Therapy 60 Eltrombopag 60 Ceflatonin R 60 aerosolized AAT 60 Cinacalcet HCl 60 INCB# [001] 60 Awarded Qualifying Therapeutic 60 Improves Survival 60 Nexavar ® 60 Allovectin 7 60 Cancer Vaccines 60 HepaGam B 60 BENLYSTA TM 60 Regeneron Pharma 60 Prodarsan 60 sNDAs 60 Virulizin ® 60 Tibotec Therapeutics division 60 BioDelivery Sciences Announces 60 Kinase Inhibitor 60 LymphoStat B TM 60 ACAPODENE R 60 synthetic siRNA 60 Demonstrates Significant 60 Saxagliptin 60 Anti CD# Antibody 60 Aptamer 60 IMA# 60 Disease Modifying 60 KIACTA ™ 60 Submits Investigational 60 Initiates Clinical Trials 60 RhuDex ® 60 Treatment IND 60 Begins Dosing 60 InterfeRx 60 Rigel R# 60 Signaling Pathway 60 Employment Inducement Awards 60 refractory Hodgkin lymphoma 60 Cimzia certolizumab pegol 60 Receives CE Marking 60 methylnaltrexone 60 Eraxis 60 Dacogen injection 60 Cloretazine ® 60 ankylosing spondylitis psoriatic arthritis 60 Novel Oral 60 Small Molecule 60 Pfizer Sutent 60 CONBRIZA 60 Tentative Approval 60 topical NSAID 60 Alogliptin 60 mitogen activated ERK kinase 60 Novel Compound 60 ZEFTERA ™ 60 SPL# Gel vaginal microbicide 60 SEBIVO 60 Polyphenon ® E 60 Taiho Pharmaceutical 60 OvaRex R 60 Prodarsan R 60 Humira adalimumab 60 RAPAFLO 60 Autoimmune Disease 60 ibuprofen Injection 60 Stem Cell Treatment 60 Demonstrates Positive 60 Aloxi R 60 Pulmonary Arterial Hypertension 60 Genasense R 60 levocetirizine 60 prasterone 60 Cx# [002] 60 Immunomedics Announces 60 Abstral ® 60 SUPPRELIN R LA 60 Azacitidine 60 Rhucin ® recombinant 60 Acute Radiation Syndrome ARS 60 Earns Milestone Payment 60 INSPIRE Trial Phase III 60 Advagraf 60 ATryn ® 60 GW# [003] 60 Vaccine Candidate 60 Prestara 60 therefore therapeutically equivalent 60 hyaluronidase enzyme 60 Presents Preclinical 60 Fodosine 60 ATL# [001] 60 Arzerra ofatumumab 60 oropharyngeal candidiasis 60 lintuzumab SGN 60 NPC 1C 60 dihydrochloride Tablets 60 Testosterone MDTS ® 60 Arranon 60 Talabostat 60 PF # [002] 60 Nasdaq HALO 60 Zolinza 60 arsenic trioxide injection 60 Degarelix 60 ularitide 60 Clinical Trial Evaluating 60 Onalta 60 Sevelamer 60 efalizumab 60 Therapeutic Vaccine 60 modified glutathione analog 60 Homspera TM 60 balsalazide disodium 60 PREOS R 60 ALVESCO R 60 LymphoStat B belimumab 60 GSK# [001] 60 Antitumor 60 Ecallantide 60 Poniard Pharmaceuticals Announces 60 Soriatane 60 interferon gamma 1b 60 Preclinical Efficacy 60 Xyrem ® 59 intravesical infusion therapy 59 ZEFTERA TM Zevtera TM 59 THALOMID R 59 Biomarker Study 59 Solazed ™ 59 Actimmune ® 59 Gastric Cancer 59 Phase III Pivotal 59 acyclovir Lauriad R 59 PDE4 inhibitor 59 product platforms AZX# 59 Drug Fails 59 Vicriviroc 59 Combination Therapy 59 etanercept Enbrel 59 Pazopanib 59 Release Capsules 59 pediatric exclusivity 59 Investigational Device Exemption 59 Dalbavancin 59 Firdapse TM amifampridine phosphate 59 Pixantrone 59 sitaxsentan sodium 59 MKC# MKC# PP 59 granted orphan 59 eprodisate Fibrillex TM 59 StaphVAX R 59 Combo Therapy 59 herpetic keratitis 59 Æterna Zentaris 59 Marketing Authorization Application 59 Lenalidomide 59 Lenocta TM 59 Mg Uk 59 Pivotal Phase II 59 Severe Sepsis 59 PrevOnco ™ 59 Colorectal Cancer Patients 59 Government Qualifying Therapeutic 59 Chemokine Receptor 59 Solzira TM 59 targeted antifolate 59 ACOMPLIA R 59 XYOTAX TM 59 HuMax EGFr 59 Intravenous CP 59 Genasense ® 59 PROMACTA 59 solifenacin succinate 59 Besivance 59 PEG SN# 59 equine osteoarthritis marketed 59 human C1 inhibitor 59 Respiratory Distress 59 Vion Pharmaceuticals 59 Ambrisentan 59 Fidaxomicin 59 Announce License Agreement 59 Demonstrates Potent 59 Torisel temsirolimus 59 Tofacitinib 59 Orphan Drug Act 59 Tesamorelin 59 XL# anticancer compounds 59 Bayer Nexavar 59 Anemia Drug 59 P#X# antagonist 59 trastuzumab Herceptin R 59 defensin mimetic antibiotic 59 Potent Antiviral Activity 59 markets Gelclair R 59 histamine dihydrochloride 59 systemic juvenile idiopathic 59 FIRMAGON R 59 cutaneous T 59 SEASONALE R 59 Thrombin topical Recombinant 59 Full Prescribing Information 59 LymphoStat B 59 Therapeutic Antibodies 59 Rheumatoid Arthritis Patients 59 Ebola Vaccine 59 Preotact 59 budesonide foam 59 Plenaxis R 59 Antiangiogenic 59 Pivotal Trials 59 submitted supplemental Biologics 59 Raptiva ® 59 BLP# Liposome Vaccine 59 Protexia ® 59 Gleevec Glivec 59 Eprodisate KIACTA TM 59 Hematide ™ 59 novel synthetic PEGylated 59 HCl capsules 59 markets HP Acthar 59 equine osteoarthritis 59 Oracea ® 59 Exalgo TM 59 pseudobulbar affect PBA 59 Silenor ® 59 daptomycin 59 PDX pralatrexate 59 Aganocide 59 visit smith.com 59 Aloxi ® 59 Arcalyst 59 ENLIGHT 59 ganetespib 59 ORADUR ® 59 Tasimelteon 59 Bendamustine 59 Hypoactive Sexual Desire Disorder 59 Phase #b/#a clinical 59 Increlex TM 59 PRTX 59 Vidaza azacitidine 59 compound ISA# 59 AstraZeneca Symbicort 59 ATPace TM 59 KRN# 59 candidate REP# 59 XL# XL# XL# XL# 59 Boxed Warning 59 JAK inhibitor 59 Study Showed 59 molecular imaging radiopharmaceutical 59 Boceprevir 59 Zebinix R 59 SUTENT ® 59 ZADAXIN ® 59 subsidiaries visit http:/www.apricusbio.com 59 submitted Biologics License 59 Remicade infliximab 59 SFDA Approval 59 Angiox ® 59 Panzem 59 PROGENSA R 59 TM pralatrexate injection 59 Gleevec imatinib 59 ZOLINZA 59 Phase IIa Clinical Trial 59 Molecular Diagnostic Test 59 miconazole Lauriad R 59 Arzerra TM 59 XIAPEX ® 59 Obtains CE Mark 59 Demonstrates Potential 59 Diabetic Macular Edema 59 STEDESA 59 registrational trial 59 ASONEP 59 SURFAXIN 59 IMiD 59 cyclobenzaprine hydrochloride extended 59 erlotinib Tarceva ® 59 forodesine 59 small molecule thrombopoietin 59 Desvenlafaxine Succinate 59 TORISEL TM 59 product candidate Lpathomab 59 REMOXY POSIDUR ELADUR 59 OvaRex ® MAb 59 volociximab 59 sapropterin dihydrochloride 59 Ocrelizumab 59 Spectrum Pharmaceuticals Announces 59 Adjunctive Therapy 59 catheter occlusion 59 Entereg R 59 Diabetic Nephropathy 59 See CLINICAL PHARMACOLOGY 59 Seasonal Influenza Vaccine 59 Aurora Kinase 59 ATG Fresenius S 59 Breast Cancer Recurrence 59 liposomal formulation 59 Advanced Colorectal Cancer 59 Anturol TM 59 Luveniq 59 Zenapax 59 Shows Promise Against 59 Plicera 59 NYSE Amex Listing 59 prokinetic agent 59 Dynepo TM 59 tiapamil 59 AVANIR Pharmaceuticals Announces 59 Voreloxin 59 Composite Coatings 59 refractory cutaneous T 59 Regulatory Approval 59 Plaque Psoriasis 59 RhuDex 59 oral cladribine 59 #D#C# 59 visit http:/www.mannkindcorp.com 59 alvimopan 59 Opterone R 59 Treated Patients 59 Restanza 59 PEGINTRON TM 59 Submits IND 59 Anti Tumor Activity 59 ZACTIMA 59 II Clinical Trial 59 Universal Flu Vaccine 59 LEVADEX TM 59 Treating Chronic 59 Improves Outcomes 59 Clinical Trial Data 59 Drug Eluting Stent 59 TRANSDUR Sufentanil 59 FDA Okays 59 Nalmefene 59 FDA Approval 59 Develop Novel 59 orphan medicinal 58 CD# CEA 58 Tasigna nilotinib 58 Acetavance TM 58 candidate XP# 58 supplemental Biologics License Application 58 TRISENOX R 58 B lymphocyte stimulator 58 anidulafungin 58 investigational therapies 58 Fludara ® 58 Salix Pharma 58 Hematological Malignancies 58 recombinant thrombin 58 Nimotuzumab 58 Medical Countermeasures 58 OHR/AVR# 58 Sebivo 58 TELINTRA 58 Tygacil 58 Restanza TM 58 Key Milestones 58 Amigal TM 58 Vidofludimus 58 BioNumerik 58 Receptor Agonist 58 HCV protease inhibitors 58 Phase III Clinical Trials 58 hypereosinophilic syndrome 58 Deferiprone 58 MEK inhibitor 58 personalized cellular immunotherapy 58 Initiates Phase 58 Collaborators Present 58 include Phenoptin TM 58 buccal tablets 58 Telavancin 58 Increlex ® 58 AzaSite Plus 58 Microplasmin 58 PLK1 SNALP 58 pain palliation 58 InNexus Biotechnology 58 Voluntary Withdrawal 58 Antiviral Drugs 58 induced macular edema 58 PGL# 58 Japanese Encephalitis Vaccine 58 Darunavir 58 DPX Survivac 58 class mGluR5 inhibitor 58 Cerashield ™ 58 oxaliplatin Eloxatin 58 Zarnestra 58 relapsing multiple sclerosis 58 GSK '# 58 Pivotal Clinical Trial 58 Renal Function 58 valtorcitabine 58 Nasdaq Deficiency Notice 58 ® decitabine 58 Everolimus 58 Clavis Pharma 58 Subgroup Analysis 58 KNS # 58 Pharmacokinetic Study 58 Glucophage XR 58 Drug Shows Promise 58 Stedesa 58 IAP inhibitor 58 Evoltra TM 58 RECOTHROM R 58 Filgrastim 58 Somatuline Autogel 58 Iluvien TM 58 phase IIb clinical 58 Receives Tentative Approval 58 ThermoDox ® 58 recurrent metastatic ovarian cancer 58 oral ridaforolimus 58 Idiopathic Pulmonary Fibrosis 58 Application MAA 58 faropenem 58 Avastin bevacizumab 58 maribavir 58 Keryx Biopharma 58 Vpriv 58 TM Drug Eluting 58 Medidur ™ FA 58 Darbepoetin Alfa 58 Hepatitis C Virus HCV 58 ONSOLIS 58 Anthim 58 eltrombopag 58 Commence Phase 58 AzaSite TM 58 FDA Clears 58 Unresectable 58 Augment ™ 58 Nycomed GmbH 58 faropenem medoxomil 58 donepezil hydrochloride 58 directed radiotherapeutic antibody 58 CERVARIX R 58 TORISEL 58 Tumor Targeting 58 microRNA Therapeutics 58 TYGACIL 58 Randomized Phase 58 Morquio 58 Leukine 58 Thalidomide Pharmion #mg 58 Interferon Gamma 58 mTOR inhibitor 58 Campath alemtuzumab 58 photoprotective drug 58 Roche Actemra 58 Sudhir Agrawal D.Phil 58 thymalfasin 58 PANVAC VF 58 By JAMAAL ABDUL 58 Combidex 58 MAA submission 58 oral taxane 58 Sunesis Pharma 58 Oral Spray 58 HP Acthar Gel repository 58 Topical Treatment 58 SILENOR 58 Alvesco R 58 DARA logo 58 CYCLOSET ® 58 R#/MEM # 58 Generic Protonix 58 Shows Statistically Significant 58 Fentanyl Patch 58 Adenuric R 58 candidate Zenvia 58 Herceptin trastuzumab 58 tramiprosate ALZHEMED TM 58 Modrenal R 58 ISTODAX 58 huC# DM4 58 Lucanix R 58 Dose Ranging Study 58 LUVENIQ 58 Osteoporosis Drug 58 Bioral ® 58 Estrogen Receptor 58 Serdolect ® 58 Voraxaze 58 drug pipeline TAFA# 58 NetLogic Microsystems Reports Inducement 58 OMP #R# 58 ixabepilone 58 Nasdaq Delisting Notification 58 Fondaparinux 58 Act PDUFA date 58 Augment TM 58 dirucotide MBP# 58 casopitant 58 Evoltra 58 BioSante Pharmaceuticals Announces